8.4.09
Fort Lauderdale, Florida
OmniComm Systems (Fort Lauderdale, FL) has acquired the EDC assets of UK-based Logos Technologies, who has U.S. headquarters in Arlington, VA. The acquisition will be led by OmniComm's UK subsidiary OmniComm Ltd. and provide the parent company with EDC products that cover all aspects of the Phase I process, including subject recruitment, clinical workflow management, and laboratory samplemanagement.
"We are pleased to add the Logos products and operations to the OmniComm team,” said Cornelis F. Wit,
OmniComm's President and CEO, in a company press release. "We believe that the addition of the Logos Phase I products is of importance for OmniComm Systems, as it will broaden the scope of our integrated eClinical solutions offering. Only a very small number of EDC companies specialize in the Phase I market, therefore this acquisition represents animportant addition to our overall corporate growth strategy."
OmniComm reports that the new Logos products will complement their TrialMaster software, which is primarily used in later stage clinical trials.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.